Find information on thousands of medical conditions and prescription drugs.

Familial Alzheimer disease

Familial Alzheimer's disease (FAD) is an uncommon form of Alzheimer's disease that comes on earlier in life (usually between 30 and 60 years of age) and is inherited in an autosomal dominant fashion. While it only accounts for 5% or less of total Alzheimer's disease, it has presented a useful model in studying various aspects of the disorder. more...

Home
Diseases
A
Aagenaes syndrome
Aarskog Ose Pande syndrome
Aarskog syndrome
Aase Smith syndrome
Aase syndrome
ABCD syndrome
Abdallat Davis Farrage...
Abdominal aortic aneurysm
Abdominal cystic...
Abdominal defects
Ablutophobia
Absence of Gluteal muscle
Acalvaria
Acanthocheilonemiasis
Acanthocytosis
Acarophobia
Acatalasemia
Accessory pancreas
Achalasia
Achard syndrome
Achard-Thiers syndrome
Acheiropodia
Achondrogenesis
Achondrogenesis type 1A
Achondrogenesis type 1B
Achondroplasia
Achondroplastic dwarfism
Achromatopsia
Acid maltase deficiency
Ackerman syndrome
Acne
Acne rosacea
Acoustic neuroma
Acquired ichthyosis
Acquired syphilis
Acrofacial dysostosis,...
Acromegaly
Acrophobia
Acrospiroma
Actinomycosis
Activated protein C...
Acute febrile...
Acute intermittent porphyria
Acute lymphoblastic leukemia
Acute lymphocytic leukemia
Acute mountain sickness
Acute myelocytic leukemia
Acute myelogenous leukemia
Acute necrotizing...
Acute promyelocytic leukemia
Acute renal failure
Acute respiratory...
Acute tubular necrosis
Adams Nance syndrome
Adams-Oliver syndrome
Addison's disease
Adducted thumb syndrome...
Adenoid cystic carcinoma
Adenoma
Adenomyosis
Adenosine deaminase...
Adenosine monophosphate...
Adie syndrome
Adrenal incidentaloma
Adrenal insufficiency
Adrenocortical carcinoma
Adrenogenital syndrome
Adrenoleukodystrophy
Aerophobia
Agoraphobia
Agrizoophobia
Agyrophobia
Aicardi syndrome
Aichmophobia
AIDS
AIDS Dementia Complex
Ainhum
Albinism
Albright's hereditary...
Albuminurophobia
Alcaptonuria
Alcohol fetopathy
Alcoholic hepatitis
Alcoholic liver cirrhosis
Alektorophobia
Alexander disease
Alien hand syndrome
Alkaptonuria
Alliumphobia
Alopecia
Alopecia areata
Alopecia totalis
Alopecia universalis
Alpers disease
Alpha 1-antitrypsin...
Alpha-mannosidosis
Alport syndrome
Alternating hemiplegia
Alzheimer's disease
Amaurosis
Amblyopia
Ambras syndrome
Amelogenesis imperfecta
Amenorrhea
American trypanosomiasis
Amoebiasis
Amyloidosis
Amyotrophic lateral...
Anaphylaxis
Androgen insensitivity...
Anemia
Anemia, Diamond-Blackfan
Anemia, Pernicious
Anemia, Sideroblastic
Anemophobia
Anencephaly
Aneurysm
Aneurysm
Aneurysm of sinus of...
Angelman syndrome
Anguillulosis
Aniridia
Anisakiasis
Ankylosing spondylitis
Ankylostomiasis
Annular pancreas
Anorchidism
Anorexia nervosa
Anosmia
Anotia
Anthophobia
Anthrax disease
Antiphospholipid syndrome
Antisocial personality...
Antithrombin deficiency,...
Anton's syndrome
Aortic aneurysm
Aortic coarctation
Aortic dissection
Aortic valve stenosis
Apert syndrome
Aphthous stomatitis
Apiphobia
Aplastic anemia
Appendicitis
Apraxia
Arachnoiditis
Argininosuccinate...
Argininosuccinic aciduria
Argyria
Arnold-Chiari malformation
Arrhythmogenic right...
Arteriovenous malformation
Arteritis
Arthritis
Arthritis, Juvenile
Arthrogryposis
Arthrogryposis multiplex...
Asbestosis
Ascariasis
Aseptic meningitis
Asherman's syndrome
Aspartylglycosaminuria
Aspergillosis
Asphyxia neonatorum
Asthenia
Asthenia
Asthenophobia
Asthma
Astrocytoma
Ataxia telangiectasia
Atelectasis
Atelosteogenesis, type II
Atherosclerosis
Athetosis
Atopic Dermatitis
Atrial septal defect
Atrioventricular septal...
Atrophy
Attention Deficit...
Autoimmune hepatitis
Autoimmune...
Automysophobia
Autonomic dysfunction
Familial Alzheimer disease
Senescence
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Clinical features

Alzheimer disease (AD) is the most common form of dementia. It usually occurs in old age, and starts gradually with early signs being forgetfulness, particularly in remembering recent events and the names of people and things. There may be some other cognitive difficulties early on, but nothing overly alarming.

As the disease progresses, the patient may start to exhibit greater problems. They may forget how to do simple things such as brushing their hair, and later in the disease may become anxious or aggressive, ultimately needing full-time care.

Familial Alzheimer disease is an uncommon form of Alzheimer's that comes on earlier in life (usually between 30 and 60 years) and is inherited in an autosomal dominant fashion. There are a number of types of familial (or early-onset) AD, which are identified by their genetics and other characteristics such as the age of onset. As a whole, this form of the disease only accounts for roughly 10% to 15% of all cases of AD.

Histologically, familial AD is practically indistinguishable from other forms of the disease. Deposits of amyloid can be seen in sections brain tissue (visible as an apple-green yellow birefringence under polarised light). This amyloid protein forms plaques and neurofibrillary tangles that progress through the memory centres of the brain. Very rarely the plaque may be unique, or uncharacteristic of AD; this can happen when there is a mutation in one of the genes that creates a functional, but malformed, protein instead of the ineffective gene products that usually result from mutations.

Genetic causes and mutations

There are multiple genetic causes of Alzheimer disease. Two of these are the presenilin polymorphisms on chromosomes 1 and 14, Others include several amyloid precursor protein polymorphisms and one of the four common alleles of apolipoprotein E. Several other gene polymorphisms have also been identified to increase susceptibility to Alzheimer's.

PSEN1 - Presenilin 1

The presenilin 1 gene (PSEN1) was linked to the long arm of chromosome 14 (14q24.3) using a pedigree of 34 people suffering from early-onset Alzheimer disease by Campion (1995). The actual gene was identified by Sherrington (1995) to be PSEN1, and multiple mutations were identified. Mutations in this gene cause familial Alzheimer's type 3. This protein has been identified as part of the enzymatic complex that cleaves amyloid beta peptide from APP (see below).

The gene contains 14 exons, and the coding portion is estimated at 60 kb, as reported by Rogaev (1997) and Del-Favero (1999). The protein the gene codes for (PS1) is an integral membrane protein. As stated by Ikeuchi (2002) it cleaves the protein Notch1 so is thought by Koizumi (2001) to have a role in somitogenesis in the embryo. It also has an action on an amyloid precursor protein, which gives its probable role in the pathogenesis of FAD. Homologs of PS1 have been found in plants, invertebrates and other vertebrates.

Read more at Wikipedia.org


[List your site here Free!]


Naturopathic Approach to Alzheimer's Disease
From Townsend Letter for Doctors and Patients, 7/1/01 by Dr. Farhang Khosh

Alzheimer's disease is perhaps the most important of all the degenerative diseases today because of its frequent occurrence and devastating nature. It is the most common cause of dementia in the elderly, with all that this implies in the way of distress for patients and families and economic loss in the form of the costs entailed in the long-term care of patients totally disabled by the disease. Historically, the term Alzheimer's disease was applied to progressive dementia coming on in late middle life but preceding the senile period, following the original description by Alois Alzheimer in 1907, in which the illness of a woman dying at the age of 55 was depicted clinically and pathologically. [1]

There are many different etiologies contributing to the pathogenesis, though this is a summary of the most important ones. The outstanding pathologic feature is death and disappearance of nerve cells in the cerebral cortex. This leads ultimately to extensive convolutional atrophy especially in the frontal, parietal, and medial temporal regions. There is a corresponding enlargement of the ventricular system, but this is usually not extreme. Two kinds of microscopic lesions are distinctive for the disease. The first, originally described by Alzheimer, consists of intraneuronal accumulations of filamentous material in the form of loops, coils, or tangled masses -- referred to as Alzheimer neurofibrillary tangles. The neuropathologic evidence strongly suggests that these fibrillar masses are of major importance in bringing about the death of neurons. Neurofibrillary tangles and loss of synapses are the neuropathologic features most closely linked to dementia. The other histopathologic change that characterizes Alzheimer's disease is the presence of intracortical clusters of thickened neuronal processes, both axons and dendrites (collectively referred to as neurites), generally in the form of an irregular ring surrounding a spherical deposit of amyloid fibrils. These lesions, which had been recognized before Alzheimer's description of the neurofibrillary change, were termed senile plaques. Recent elucidation of their structure has led to their current designation as neuritic plaques. They have been shown to contain paired helical filaments identical to those found in the perinuclear cytoplasm of the diseased neurons. One form of plaque, the diffuse plaque, consists of amorphous amyloid without neurites. [2]

The amyloid peptide (B or A4 peptide) gene is on chromosome 21, on which the familial Alzheimer's disease gene also has been localized in some families. A recent advance has been the finding that in a handful of families with familial Alzheimer's disease there are point mutations in the amyloid precursor protein. This observation suggests that Alzheimer's disease can be linked to a primary defect in amyloid production or processing, but most cases of familial and sporadic Alzheimer's disease do not have a clear cause. [2]

Biochemical studies show that choline acetyltransferase, the key enzyme required for the synthesis of acetylcholine, is decreased in the cerebral cortex in Alzheimer's disease. The major source of neocortical cholinergic innervation is a group of neurons situated in the basal part of the forebrain just beneath the corpus striatum -- the nucleus basalis of Meynert. Careful neuropathologic investigations have shown that in Alzheimer's disease this nucleus is a site of major neuronal loss and of frequent Alzheimer neurofibrillary tangles. These studies suggest that impairment of cholingergic transmission may play a part in the clinical expression of the disease. [3]

The rule of neurotoxic chemicals such as Aluminum, [4] Mercury fillings, [5] and neurotoxic food additives such as MSG have been discussed in many articles to be the etiology of Alzheimer's disease.

Certain areas of the brain show greater vulnerability to glucose deprivation. They are the same temporal and parietal regions wherein the characteristic deficits in Alzheimer's disease (AD) are shown by PET and SPECT imaging studies.

Senile plaques and associated neurofibrillary tangles are probably the direct cause of Alzheimer's disease. The principal component of senile plaques is the beta amyloid of protein. There appears to be a reduction in essential fatty acids, with a corresponding increase in saturated fatty acids. This results in increased permeability of cellular membranes and a reduction in membrane fluidity. Consequently, the cellular membranes of Alzheimer's diseased brains might be penetrated by the enzyme that could cut the beta-amyloid precursor protein ([beta]-APP). This would release a large fragment of this protein into the extracellular space with the beta-amyloid section intact. Essential fatty acid deficiency will also reduce prostaglandins. Another pathogenesis of Alzheimer's disease is said to be deficiency of essential fatty acids which results in prostaglandin reduction. [6]

Clinical Appearance

The onset of Alzheimer's disease is insidious and subtle, with changes most noticeable first in memory for recent happenings and in other aspects of mental activity. Psychiatric disturbances such as depression, anxiety, or odd, unpredictable quirks of behavior, delusions, and hallucinations may be silent features in the early stages. Progression is usually slow and gradual, and unless other medical conditions supervene, it may smolder on for 10 or more years. In the milder case, including those of the senile period, the noteworthy features are those of simple dementia. More unusual disorders of thought and intellect, including aphasia, apraxic disturbances, and abnormalities of space perception, may be seen, especially in the presenile group. Exceptionally, and only in the advanced stages of the disease, extrapyramidal signs appear; the patient walks in a shuffling manner with short steps, and there is a generalized stiffness of the musculature with slowness and awkwardness of all movements. In some patients, sudden jerky contractions of various muscles (myoclonus) may occur in the presence of otherwise typical Alzheimer's disease, but this is unusual and should immediately raise the suspicion of Creutzfeldt-Jakob disease. Terminally, the patient may become nearly decorticate, losing all ability to perceive, think, speak or move. [2]

Relevant labs, Special tests and Imaging

CBC, chemistry panel, thyroid function studies, folate and B12 levels, VDRL, UA, EKG, EEG, CSF, Head CT/MRI and PET. [7]

Differential Diagnosis [8]

1. Vascular dementia

2. Multi-infarct dementia

3. Dementia associated with Parkinson's

4. Creutzfeldt-Jakob disease

5. End-stage multiple sclerosis

6. Brain tumor

7. Subdural hematoma

8. Progressive multifocal leukoencephalopathy

9. Metabolic dementia (hypothyroidism)

10. Drug reactions

11. Alcoholism and other addictions

12. Dementia pugilistica

13. Depression

14. Toxicity from liver or kidney failure

15. Vitamin and other nutritional deficiencies

Treatment

There are many treatment approaches that have been suggested for Alzheimer's disease. In this paper, I will emphasize those treatments that have been clinically proven effective. This is by no means the only available treatment.

1. Acetyl-Carnitine: L-carnitine is required for mitochondrial transport of long chain fatty acids for [beta]-oxidation. Carnitine naturally occurs in the diet, particularly in animal products, and can be made from the essential amino acids lysine and methionine. Carnitine is produced in the liver and the kidney and requires several other nutrients, including vitamin C, niacin, vitamin B6 and iron, for its synthesis. Recently a multicenter trial giving acetyl-carnitine at 2 gins per day for one year affected the progression of cognitive and functional impairment in Alzheimer's disease. This was a placebo, double-blind trial. The 2 gm doses were well tolerated. Acetyl-L-carnitine induces acetyl-carnitine release in the striatum and hippocampus. Acetyl-carnitine also increases membrane cytoskeletal protein-protein interactions. [9]

2. Anti-oxidants such as Vitamin A (5,000-20,000 I.U. a day), E (2,000-3,000 I.U. a day), C (500-3,000 mg a day), Selenium (400 mcg a day) and Carotenoids: In one study the results showed that both Alzheimer's and multi-infarct dementia patients had significantly lower levels of vitamins E and beta-carotene than controls. Vitamin A was significantly reduced only in Alzheimer's disease patients. Since vitamins A, E and beta-carotene act as antioxidants, reduced levels could result in increased degeneration of the nervous system, exacerbating the dementia. It would be interesting to see if lipid-soluble vitamin supplements alter the rate of the progression of the dementia. [10]

3. Zinc (15-60 mg a day): The hippocampus is the area of the brain with the highest zinc concentration. Studies show that chronic neuroleptic medication increases amyloid induced production of NFT (neurofibrillary tangles), while zinc compounds can inhibit amyloid-induced production of neuronal paired-helical filaments. Preliminary trials with zinc aspartate have shown promise. [11]

4. Improve mitochondrial function: Mutated mitochondrial DNA is associated with cellular dysfunction in close association with the brains of Alzheimer's patients. By improving mitochondrial function with vitamins B2, menadione (vitamin K) and coenzyme Q10, the function of SDAT (senile dementia of the Alzheimer type) patients may be temporarily improved by enhancing some impaired neurons and slowing mitochondrial decline. Coenzyme Q10, sodium ferrous citrate, and vitamin B6 have shown a benefit in improving mental function. [12]

5. Vitamin B12: Studies evaluated relationship between Vitamin B12 and dementia in Alzheimer's disease. The deficiency of Vitamin B12 is prevalent in Alzheimer's patients and must be screened. [13]

6. Estrogen: Epidemiological study suggests that estrogen protects women against Alzheimer's disease. Women using estrogen replacement therapy were 40% less likely to have Alzheimer's disease and related dementias compared to women not on estrogens. [14]

7. Thiamine: Activities of thiamine-dependent enzymes (pyruvate dehydro-genase (PDHC), alpha-ketoglutarate dehydrogenase ([alpha]-KGDH), and transketolase (TK)) were measured in autopsied samples of temporal cortex from six patients with Alzheimer's disease and from eight age- matched control subjects who were free from neurological or psychiatric diseases. Significant decreases in PDHC, decreases were by 70%; [alpha]-KGDH, decreased by 70%; and TK, decreased by 52%; were observed in brain tissue from patients with Alzheimer's. [15]

8. NADH: In one study all patients showed improvement in cognitive and functional capacity. The mechanism of action of NADH is believed to be an increased synthesis of neurotransmitters, particularly dopamine and norepinephrine, in the brain; NADH is also believed to increase intracellular energy production. [16]

9. Botanicals:

a. Huperizia serata, a Chinese tea contains Huperzine A and this increases acetylcholine levels in the brain. Thereby improves cognitive function. [17,21]

b. Lycorus radiata (shisuan), a Chinese herb, contains the alkaloids lycorine, lycoramine, lycoreine, and galanthamine. Both lycoramine and galanthamine have been shown to be reversible cholinesterase inhibitors. [17]

c. Macleaya cordata (boluohui), a Chinese herb, contains several alkaloids including sanguinarine, chelerythine, protopine, and allocryptopine. Sanguinarine inhibits cholinesterase. [17]

d. Coptis chinensis (huanglian), a Chinese herb, contains berberine alkaloids, mainly berberine, but also coptisine, worenine, palmatine, and columbamine. Berberine is a cholinesterase inhibitor. [17]

e. Berberis species (sankezhen), a Chinese herb, also contains berberine and palmatine that have a strong anticholinesterase activity. [17]

f. Securinega suffruticosa (yiyiqiu), a Chinese herb, contains many alkaloids, mainly securinine and its derivatives. Securinine is a CNS stimulant that antagonizes the inhibitory action of meprobamate. Securinine inhibits cholinesterase activity. [17]

g. Solanum nigrum (longkui), a Chinese herb, contains solanine, salasodine. Solanine has a strong anticholinesterase action. [17]

h. Physostigma venenosum from the calabar bean blocks the action of acetylcholinesterase. [18]

i. Pilocarpus jaborandi contains pilocarpine that has a M1 mimetic activity, which can affect the M1 receptor site and take the place of acetylcholine in neurotransmission in the Nucleus basalis of Maynard. [18]

j. Hawthorne berry, Blueberry, Elderberry, Red and Black grapes improve the integrity of blood vessel walls via anthocyanins. [18]

k. Ginkgo / Gotu kola / Zizyphus jujube improves memory. [18]

l. Ginkgo biloba/Salvia officinalis / Melissa officinalis, ginkgo contains the ginkgolides which have antioxidant, neuroprotective and cholinergic activities relevant to Alzheimer's disease mechanisms. The therapeutic efficacy of Ginkgo extracts in Alzheimer's disease in placebo controlled clinical trials is reportedly similar to currently prescribed drugs such as tacrine or donepezil and, importantly, undesirable side effects of Ginkgo are minimal. Old European reference books, such as those on medicinal herbs, document a variety of other plants such as Salvia officinalis (sage) and Melissa officinalis (balm) with memory-improving properties, and cholinergic activities have recently been identified in extracts of these plants. [19]

m. Periwinkle / Hydrocotyle asiatica increases cerebral circulation and function. [20]

References

(1.) Isselbacher, Braunwald, Wilson, Martin, Fauci, Kasper. Harrison's Principles of Internal Medicine 13th edition. 1994. McGraw-Hill, Inc., New York. Pg. 2270.

(2.) Isselbacher, Braunwald, Wilson, Martin, Fauci, Kasper. Harrison's Principles of Internal Medicine 13th edition. 1994. McGraw-Hill, Inc., New York. Pg. 2271.

(3.) Butterfield, A. Acetylcarnitine increases membrane cytoskeletal protein-protein interactions. 1993. Life Science. Pgs. 297-303.

(4.) Woodruff, M. and Nonneman A. Toxin-Induced Models of Neurologic Disorders. 1994. Plenum Press. Pgs. 301-318.

(5.) Terry, RD., Katzman, R. and Bick, KL. Brain Trace Elements in Alzheimer's disease. Alzheimer's Disease. 1994. Raven Press. New York.

(6.) Newman, P. Could Diet be One of the Causal Factors of Alzheimer's Disease. Medical Hypothesis. 1992. Pgs. 123-126.

(7.) Dambro, M. Griffith's Five Minute Clinical Consult. 1995. Williams & Wilkins, Baltimore, Maryland. Pg. 24.

(8.) Dambro, M. Griffith's Five Minute Clinical Consult. 1995. Williams & Wilkins, Baltimore, Maryland. Pg. 24.

(9.) Bowman, B. Acetyl-Carnitine and Alzheimer's Disease. Nutrition Reviews. 1992:50(5): Pgs. 142-144.

(10.) Zaman, C. Plasma concentrations of Vitamins A and E and Carotenoids in Alzheimer's Disease. Age and Aging. 1992:21: Pgs. 91-94.

(11.) Constantinidis, J. Treatment of Alzheimer's Disease by Zinc Compounds. Drug Development Research. 1992;27: Pgs. 1-14.

(12.) Harman, D. Free Radical Theory of Aging A Hypothesis on Pathogenesis of Senile Dementia of the Alzheimer's Type. Age. 1993:16: Pgs. 23-30.

(13.) Cunha, G., Rocha, L., Peixoto, M., Motta, F., Barbosa, T. Vitamin B12 deficiency and dementia. Int Psychogeriatr. 1995: 7(1): Pgs. 85-8.

(14.) Johnson, R. Estrogen/Alzheimer's Link Found. Medical Tribune. 1993: Pg. 1,8.

(15.) Butterworth, F. and Besnard, M. Thiamine-dependent enzyme changes in temporal cortex of patients with Alzheimer's disease. Metab-Brain-Dis. 1990:5(4): Pgs. 179-84.

(16.) Birkmayer, JGD. Coenzyme nicotinamide adenine dinucleotide. New therapeutic approach for improving dementia of the Alzheimer type. Ann Clin Lab Sci. 1996:26: Pgs. 1-9.

(17.) Dharmananda, S. Traditional Chinese Specific Condition Review: Alzheimer's Disease. Protocol Journal of Botanical Medicine. 1995:2(1): Pgs. 114-118.

(18.) Mitchell, W. Naturopathic Specific Condition Review: Alzheimer's Disease. Protocol Journal of Botanical Medicine. 1995:2(1): Pgs. 107-110.

(19.) Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NS. Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. J Pharm Pharmacol 1999 May; 51(5): Pgs. 527-34.

(20.) Winston, D. Eclectic Specific Condition Review: Alzheimer's Disease. Protocol Journal of Botanical Medicine. 1995:2(1): Pg. 113.

(21.) Medical News & Perspective, Old Chinese Herbal medicine used for Fever Yields New Alzheimer Disease Therapy. Journal of American Medical Association. 1997 March 12;277;776.

COPYRIGHT 2001 The Townsend Letter Group
COPYRIGHT 2001 Gale Group

Return to Familial Alzheimer disease
Home Contact Resources Exchange Links ebay